Usefulness of microRNA‑375 as a prognostic and therapeutic tool in esophageal squamous cell carcinoma

Isozaki,Yuka; Hoshino,Isamu; Akutsu,Yasunori; Hanari,Naoyuki; Mori,Mikito; Nishimori,Takanori; Murakami,Kentaro; Akanuma,Naoki; Takeshita,Nobuyoshi; Maruyama,Tetsuro; Toyozumi,Takeshi; Takahashi,Masahiko; Suito,Hiroshi; Matsubara,Hisahiro

doi:10.3892/ijo.2014.2789

Usefulness of microRNA‑375 as a prognostic and therapeutic tool in esophageal squamous cell carcinoma

Authors:
- Yuka Isozaki
- Isamu Hoshino
- Yasunori Akutsu
- Naoyuki Hanari
- Mikito Mori
- Takanori Nishimori
- Kentaro Murakami
- Naoki Akanuma
- Nobuyoshi Takeshita
- Tetsuro Maruyama
- Takeshi Toyozumi
- Masahiko Takahashi
- Hiroshi Suito
- Hisahiro Matsubara
View Affiliations

Affiliations: Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 260‑8670, Japan
Published online on: December 9, 2014 https://doi.org/10.3892/ijo.2014.2789
Pages: 1059-1066

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to clarify the importance of microRNA‑375 (miR‑375) expression in patients with esophageal squamous cell carcinoma (ESCC) and to examine the in vivo antitumor effects of miR‑375 in a model of ESCC using a non‑viral delivery system. We estimated the miR‑375 and LDHB and AEG‑1/MTDH mRNA expression of the ESCC tumors from 85 patients. The correlation between the miR‑375 expression and clinicopathological features, including the prognosis, were evaluated. The presence of high miR‑375 expression was associated with lymphatic vessel invasion, while a low expression of miR‑375 significantly correlated with a poor prognosis for the 85 ESCC patients. We also found that there was a significant inverse correlation between the expression of miR‑375 and that of LDHB. Before the examination of miR‑375 in the in vivo assay, we confirmed that atelocollagen prolonged the accumulation of miRNA by using fluorescently‑labeled miRNA and an in vivo imaging system. We injected the miR‑375/atelocollagen complex or a control‑miRNA/atelocollagen complex into mice bearing TE2 and T.Tn xenografts via subcutaneous (s.c.) injections. The growth of both the TE2 and T.Tn tumors in the miR‑375 groups was significantly suppressed compared with that in the control‑miRNA groups. In addition, The LDHB mRNA expression of TE2 xenografts was significantly downregulated after miR‑375 treatment. In conclusion, it might be possible for the level of miR‑375 expression to be a utilized as a prognostic indicator for ESCC patients. The administration of miR‑375 using a non‑viral delivery might represent a powerful new treatment for ESCC.

View Figures

View References

1	Ruol A, Castoro C, Portale G, et al: Trends in management and prognosis for esophageal cancer surgery: twenty-five years of experience at a single institution. Arch Surg. 144:247–254. 2009. View Article : Google Scholar : PubMed/NCBI
2	Morita M, Yoshida R, Ikeda K, et al: Advances in esophageal cancer surgery in Japan: an analysis of 1000 consecutive patients treated at a single institute. Surgery. 143:499–508. 2008. View Article : Google Scholar : PubMed/NCBI
3	Hoshino I and Matsubara H: MicroRNAs in cancer diagnosis and therapy: from bench to bedside. Surg Today. 43:467–478. 2013. View Article : Google Scholar
4	Hoshino I, Matsubara H, Akutsu Y, et al: Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells. Oncol Rep. 18:585–592. 2007.PubMed/NCBI
5	Hoshino I, Matsubara H, Hanari N, et al: Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells. Clin Cancer Res. 11:7945–7952. 2005. View Article : Google Scholar : PubMed/NCBI
6	Hoshino I and Matsubara H: Recent advances in histone deacetylase targeted cancer therapy. Surg Today. 40:809–815. 2010. View Article : Google Scholar : PubMed/NCBI
7	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
8	Hua Z, Lv Q, Ye W, et al: MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One. 1:e1162006. View Article : Google Scholar
9	Nissan T and Parker R: Computational analysis of miRNA- mediated repression of translation: implications for models of translation initiation inhibition. RNA. 14:1480–1491. 2008. View Article : Google Scholar : PubMed/NCBI
10	Eulalio A, Huntzinger E, Nishihara T, Rehwinkel J, Fauser M and Izaurralde E: Deadenylation is a widespread effect of miRNA regulation. RNA. 15:21–32. 2009. View Article : Google Scholar :
11	Xu X, Chen Z, Zhao X, et al: MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma. Biochem Biophys Res Commun. 421:640–645. 2012. View Article : Google Scholar : PubMed/NCBI
12	Kinoshita T, Nohata N, Yoshino H, et al: Tumor suppressive microRNA-375 regulates lactate dehydrogenase B in maxillary sinus squamous cell carcinoma. Int J Oncol. 40:185–193. 2012.
13	Ward A, Balwierz A, Zhang JD, et al: Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene. 32:1173–1182. 2013. View Article : Google Scholar
14	He XX, Chang Y, Meng FY, et al: MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 31:3357–3369. 2012. View Article : Google Scholar
15	Lee EJ, Gusev Y, Jiang J, et al: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar
16	Dettmer M, Perren A, Moch H, Komminoth P, Nikiforov YE and Nikiforova MN: Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma. Thyroid. 23:1383–1389. 2013. View Article : Google Scholar : PubMed/NCBI
17	Nguyen HC, Xie W, Yang M, et al: Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate. 73:346–354. 2013. View Article : Google Scholar
18	Isozaki Y, Hoshino I, Nohata N, et al: Identification of novel molecular targets regulated by tumor suppressive miR-375 induced by histone acetylation in esophageal squamous cell carcinoma. Int J Oncol. 41:985–994. 2012.PubMed/NCBI
19	Kong KL, Kwong DL, Chan TH, et al: MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut. 61:33–42. 2012. View Article : Google Scholar
20	Li J, Li X, Li Y, et al: Cell-specific detection of miR-375 down-regulation for predicting the prognosis of esophageal squamous cell carcinoma by miRNA in situ hybridization. PLoS One. 8:e535822013. View Article : Google Scholar
21	Hu G, Wei Y and Kang Y: The multifaceted role of MTDH/AEG-1 in cancer progression. Clin Cancer Res. 15:5615–5620. 2009. View Article : Google Scholar : PubMed/NCBI
22	Yu C, Chen K, Zheng H, et al: Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis. Carcinogenesis. 30:894–901. 2009. View Article : Google Scholar : PubMed/NCBI
23	Kinoshita T, Hanazawa T, Nohata N, Okamoto Y and Seki N: The functional significance of microRNA-375 in human squamous cell carcinoma: aberrant expression and effects on cancer pathways. J Hum Genet. 57:556–563. 2012. View Article : Google Scholar : PubMed/NCBI
24	Chen Y, Zhang H, Xu A, et al: Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancer. Lung Cancer. 54:95–102. 2006. View Article : Google Scholar : PubMed/NCBI
25	Inaba S, Nagahara S, Makita N, et al: Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals. Mol Ther. 20:356–366. 2012. View Article : Google Scholar :
26	Banno H, Takei Y, Muramatsu T, Komori K and Kadomatsu K: Controlled release of small interfering RNA targeting midkine attenuates intimal hyperplasia in vein grafts. J Vasc Surg. 44:633–641. 2006. View Article : Google Scholar : PubMed/NCBI
27	Takei Y, Kadomatsu K, Goto T and Muramatsu T: Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer. 107:864–873. 2006. View Article : Google Scholar : PubMed/NCBI